Veracyte Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Piper Jaffray Trims PT on Veracyte (VCYT) to $12, Maintains 'Overweight'
August 14, 2015 7:33 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating but trimmed his price target on Veracyte, Inc (NASDAQ: VCYT) to $12.00 (from $13.00) following Q3 results and outook.
Quirk commented, "Veracyte reported a 37.2% yoy revenue increase to $11.9M, above our $11.7M estimate, but below... More
Veracyte (VCYT) Misses Q2 EPS by 4c
August 13, 2015 4:35 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $12.23 million.
Veracyte reaffirmed FY2015 guidance.
"We continue to see strong growth of Afirma across both community-based physicians... More
